Calcipotriol and PUVA as treatment for vitiligo.
We performed a prospective study to evaluate efficacy of the combination of calcipotriol and psoralen plus ultraviolet A (PUVA) in the treatment of vitiligo. Twenty-three patients with essentially bilateral symmetrical lesions of vitiligo were included. Calcipotriol (0.005 %) ointment was applied twice daily over the right side of the body, and the other side was not treated. PUVA was performed three times per week. All patients received at least forty five sessions of PUVA. Patients were evaluated clinically and photographed all fifteen weeks. At the fifteenth session, 69 percent of the patients had minimal to moderate improvement on the calcipotriol side compared to 52 percent on the PUVA-only side (p = 0.015). At the forty-fifth session, 52 percent showed marked improvement on the calcipotriol side compared to 30 percent on the PUVA-only side (p = 0.13), with more intense repigmentation on calcipotriol-treated areas. Treatment was well tolerated, and no adverse effect was noted. This combination was an effective treatment for vitiligo, especially in initiating repigmentation.
Department of Dermatology, La Rabta Hospital, Tunis, Tunisia. faika.cherif@voila.fr
F
F
Cherif
M I
MI
Azaiz
A
A
Ben Hamida
Osman
O
Ben
A
A
Dhari
D000279:Administration, Cutaneous; D000328:Adult; D000368:Aged; D002117:Calcitriol / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D002118:Calcium / Q000097:blood; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011701:PUVA Therapy; D010758:Phosphorus / Q000097:blood; D016896:Treatment Outcome; D014820:Vitiligo / Q000097:blood / Q000188:drug therapy*
C055085:calcipotriene; D010758:Phosphorus; D002117:Calcitriol; D002118:Calcium